Page 34 of 108
The role of the progesterone receptor (PR) in breast cancer remains a major clinical challenge. Although PR induces mammary tumor growth, its presence in breast tumors is a marker of good prognosis. We investi...
Multiple studies have shown that the tumor microenvironment (TME) of carcinomas can play an important role in the initiation, progression, and metastasis of cancer. Here we test the hypothesis that specific be...
Aberrant turnover of the actin cytoskeleton is intimately associated with cancer cell migration and invasion. Frequently however, evidence is circumstantial, and a reliable assessment of the therapeutic signif...
The increasing number of targeted therapies, together with a deeper understanding of cancer genetics and drug response, have prompted major healthcare centers to implement personalized treatment approaches rel...
The BRCA1 hereditary susceptibility gene has been studied in great depth, befitting its clear role in promoting basal type breast cancer and serous type ovarian (fallopian tube) cancer in women carrying germline ...
The first 'Advances in Circulating Tumor Cells (ACTC): from Basic Research to Clinical Practice' meeting was held in Athens, Greece, September 26–29, 2012 (abstracts, presentations and a more detailed meeting ...
Tamoxifen is widely used to treat hormone-dependent breast cancer, but its therapeutic benefit is limited by the development of drug resistance. Here, we investigated the role of estrogen G-protein coupled rec...
Epithelial-to-mesenchymal transition (EMT) promotes cell migration and is important in metastasis. Cellular proliferation is often downregulated during EMT, and the reverse transition (MET) in metastases appea...
Because of its high rate of metastasis, inflammatory breast cancer (IBC) has a poor prognosis compared with non-inflammatory types of breast cancer (non-IBC). In a recent study, Lehmann and colleagues identifi...
Latent TGFβ binding proteins (LTBPs) govern TGFβ presentation and activation and are important for elastogenesis. Although TGFβ is well-known as a tumor suppressor and metastasis promoter, and LTBP1 is elevate...
Trastuzumab is effective in human epidermal growth factor receptor 2 (HER2)-over-expressing breast and gastric cancers. However, patients may develop resistance through downstream signaling via the phosphatidy...
Breast cancer stem cells are suspected to be responsible for tumour recurrence, metastasis formation as well as chemoresistance. Consequently, great efforts have been made to understand the molecular mechanism...
Triple-negative breast cancer (TNBC), a subtype of breast cancer with negative expressions of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), is frequently diagno...
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
This article is part of a Supplement: Volume 15 Supplement 1
2022 Citation Impact
7.4 - 2-year Impact Factor
7.4 - 5-year Impact Factor
1.764 - SNIP (Source Normalized Impact per Paper)
2.408 - SJR (SCImago Journal Rank)
2023 Speed
20 days submission to first editorial decision for all manuscripts (Median)
129 days submission to accept (Median)
2023 Usage
2,432,781 downloads
1,561 Altmetric mentions